Considerable evidence suggests that insulin resistance is closely linked to Parkinson's disease (PD), leading agents aiming at treating diabetes can be regarded as new neuroprotective strategies in PD, notably glucagon-like peptide-1 (GLP-1). However, the extremely short half-life of GLP-1 due degradation by ubiquitous proteolytic enzyme limits its clinical application. In this study, we engine...